Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: Implications for HIV-1 vaccine efficacy trials

Citation
Jm. Baeten et al., Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: Implications for HIV-1 vaccine efficacy trials, J ACQ IMM D, 24(5), 2000, pp. 458-464
Citations number
25
Categorie Soggetti
Clinical Immunolgy & Infectious Disease",Immunology
Journal title
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
ISSN journal
15254135 → ACNP
Volume
24
Issue
5
Year of publication
2000
Pages
458 - 464
Database
ISI
SICI code
1525-4135(20000815)24:5<458:TIHIIA>2.0.ZU;2-F
Abstract
Background: Accurate predictions of HIV-1 incidence in potential study popu lations are essential for designing HIV-1 vaccine efficacy trials. Little i nformation is available on the estimated incidence of HIV-I in such populat ions, especially information on incidence over time and incidence while par ticipating in risk-reduction programs. Objectives: To examine time trends in HIV-1 incidence in a vaccine prepared ness cohort. Design: Prospective cohort study of female prostitutes in Mombasa, Kenya. Methods: HIV-1 incidence was determined using open and closed cohort design s. Generalized estimating equations were used to model HIV-1 and sexually t ransmitted disease (STD) incidence and sexual risk behaviors over time. Results: When analyzed as a closed cohort, HIV-1 incidence declined 10-fold during 3 years of follow-up (from 17.4 to 1.7 cases/100 person-years; p <. 001). More than 50% of the cases of HIV-1 occurred during the first 6 month s after enrollment, and 73% during the first 12 months. When analyzed as an open cohort, HIV-1 incidence density fell during the first 4 calendar year s, influenced by accumulation of lower risk participants and variations in study recruitment. Significant declines occurred in both STD incidence and high-risk sexual behaviors during follow-up. Conclusions: This study documents a dramatic decline in the risk of HIV-1 i nfection while participating in a prospective cohort, with most seroconvers ions occurring within 1 year of enrollment. Variations in HIV-1 incidence w ithin high-risk populations should be anticipated during the design of vacc ine trials.